Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending.
Published By Datamonitor
|
24 Mar 2011 |
|
CommentWire
|
Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.
Published By Datamonitor
|
14 Oct 2010 |
|
CommentWire
|
Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.
Published By Datamonitor
|
14 Aug 2008 |
|
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
Expert View
|
Novartis has agreed to acquire a controlling stake in ophthalmology specialist Alcon for around $39 billion, revealing a clear intention to drive diversification from its core prescription pharmaceutical business. Although Alcon will not come cheap, the acquisition represents a positive, long-term strategy by Novartis which faces intensifying generic competition over the next five years.
Published By Datamonitor
|
08 Apr 2008 |
|
CommentWire
|
A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.
Published By Datamonitor
|
02 Aug 2006 |
|
CommentWire
|
Novartis has bolstered its infectious disease pipeline with two acquisitions in as many days. The Swiss firm has signed a global agreement with US-based Human Genome Sciences for hepatitis C drug candidate Albuferon and made an offer for UK-based anti-infectives developer NeuTec Pharma.
Published By Datamonitor
|
07 Jun 2006 |
|
CommentWire
|
Novartis has announced a $507 million licensing deal with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate in the US, with exclusive marketing and promotion rights outside the US. This is the Swiss firm's latest step in its strategy to build a versatile hepatitis C portfolio and become a leading player in this high-growth market.
Published By Datamonitor
|
06 Jun 2006 |
|
CommentWire
|
Speedel and Novartis' Rasilez, the first, orally available direct renin inhibitor, has demonstrated in a phase III trial that it is a safe addition to the current antihypertensive armamentarium. The results clearly show that the novel agent is a viable treatment option, but whether this clinical success can translate into commercial potential remains to be seen, as further hurdles await.
Published By Datamonitor
|
18 May 2006 |
|
CommentWire
|
Driven by strong gains made by its generics business and double-digit growth from key drugs, Novartis has posted impressive Q1 sales of $8.3 billion and a 31% rise in operating profit. Bolstered by a strong pipeline and the acquisition of Chiron, it could now go on to achieve record growth in 2006.
Published By Datamonitor
|
26 Apr 2006 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.